BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Petrisor A, Peagu R, Badiu DC, Stanescu AMA, Moldoveanu AC, Fierbinteanu -Braticevici C. Can Non-Invasive Methods Be Clinically Useful for Diagnosis and Severity of Portal Hypertension? Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.99974] [Reference Citation Analysis]
3 Frigerio S, da Costa V, Costa M, Festari MF, Landeira M, Rodríguez-Zraquia SA, Härtel S, Toledo J, Freire T. Eosinophils Control Liver Damage by Modulating Immune Responses Against Fasciola hepatica. Front Immunol 2020;11:579801. [PMID: 33042162 DOI: 10.3389/fimmu.2020.579801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Khalifa A, Rockey DC. Lower Gastrointestinal Bleeding in Patients With Cirrhosis-Etiology and Outcomes. Am J Med Sci 2020;359:206-11. [PMID: 32087941 DOI: 10.1016/j.amjms.2020.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yu S, Ericson M, Fanjul A, Erion DM, Paraskevopoulou M, Smith EN, Cole B, Feaver R, Holub C, Gavva N, Horman SR, Huang J. Genome-wide CRISPR Screening to Identify Drivers of TGF-β-Induced Liver Fibrosis in Human Hepatic Stellate Cells. ACS Chem Biol 2022. [PMID: 35274923 DOI: 10.1021/acschembio.2c00006] [Reference Citation Analysis]
6 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Bochnakova T. Hepatic Venous Pressure Gradient. Clin Liver Dis (Hoboken) 2021;17:144-8. [PMID: 33868655 DOI: 10.1002/cld.1031] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]